MedTrace Logo

Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer.

NCT01341535 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-12-14

No results posted yet for this study

Summary

The investigators hypothesize that treatment adaptation to biological and anatomical changes, occurring during treatment, can increase the chance of cure at minimized or equal radiation-induced toxicity in head and neck cancer patients. This trial compares standard intensity-modulated radiotherapy (IMRT), using only pre-treatment planning 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography to adaptive 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography voxel intensity based IMRT or volumetric-modulated arc therapy (VMAT) using repetitive per-treatment planning 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography for head and neck cancer.

Conditions

  • Primary Non-operated Squamous Cell Carcinoma of Oral Cavity
  • Primary Non-operated Squamous Cell Carcinoma of Oropharynx
  • Primary Non-operated Squamous Cell Carcinoma of Hypopharynx
  • Primary Non-operated Squamous Cell Carcinoma of Larynx

Interventions

RADIATION

Adaptive dose-painting-by-numbers

Adaptive dose escalation by dose-painting-by-numbers.

RADIATION

standard intensity-modulated radiotherapy (IMRT)

Standard radiotherapy for head and neck cancer.

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Wilfried De Neve, Ph.D., M.D. · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2017-10-31
Completion
2021-07-15

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341535 on ClinicalTrials.gov